Chengdu Brilliant Biopharmaceutical Co., Ltd.
Has Chengdu Brilliant Biopharmaceutical Co., Ltd. received an FDA warning letter? Yes. FDA issued a warning letter dated September 11, 2025 concerning products containing semaglutide.
Letter facts
- Letter date
- September 11, 2025 (2025-09-11)
- Issuing office
- Center for Drug Evaluation and Research (CDER)
- Recipient type
- Manufacturer / API
- Products named
- Active pharmaceutical ingredients (APIs)Semaglutide
- Violation categories
- CGMP / insanitary conditions
Understanding these violation categories
CGMP / insanitary conditions
FDA says it observed conditions or manufacturing practices that do not meet current good manufacturing standards, potentially risking product sterility or quality. A warning letter allows the facility to provide corrective actions.
Factual Violation Summary
FDA cited failure to conduct process validation for GLP-1 API semaglutide and failure to perform identity testing on incoming raw materials, rendering APIs adulterated under CGMP; Import Alert 66-40 issued July 9, 2025.
Active Drug Ingredients
Statutory Citations & Specific Allegations
- Process validation
- Incoming raw material identity testing
More letters about Semaglutide
Recent FDA warning letters concerning Semaglutide:
- RonanRxOctober 30, 2026
- Cheap Medicine ShopSeptember 24, 2026
- Online Generic MedicineSeptember 23, 2026
- Empower PharmacySeptember 18, 2026
- Tex PeptidesAugust 24, 2026
Similar violations (CGMP / insanitary conditions)
Recent warning letters with related regulatory findings:
- Empower PharmacySeptember 18, 2026
- Harbin Jixianglong Biotech Co., Ltd.May 1, 2026
- New Life Pharma LLCApril 14, 2026
- ProRx LLCApril 7, 2026
- Thrive Health SolutionsFebruary 9, 2026
Regulatory Compliance & Editorial Standard:
The information on this page is compiled strictly from public regulatory enforcement documents published by the U.S. Food and Drug Administration (FDA) and reflects official government records at the time of issuance.
Regulatory Notice: Addressed establishments may have implemented corrective actions or entered into compliance agreements with regulatory authorities. For subsequent remedial filings or official FDA closeout letters, refer directly to the FDA.gov source link above.